Two new studies find limited evidence of the usefulness of Paxlovid (nirmatrelvir-ritonavir) to prevent the development of long COVID—but with a small reduction for older COVID-19 patients. Paxlovid is an antiviral drug approved for use in US patients 12 years an older who are at risk of developing severe complications from COVID-19 infections. Several observation studies have shown a small …
Read More »Studies show mostly poor long-COVID protection for Paxlovid
